TSX · BLCO.TO
Bausch + Lomb Corporation
CA$28.75+CA$0.19 (+0.67%)
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.3% below the high.
Loading market information…
CNQ · GREY.CN · CAD
Stock price, earnings
Quote as of Oct 29, 2026, 06:44 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CAD. Historical prices are not a forecast.
Grey Matters Health Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.44% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Grey Matters Health Inc.’s next earnings report is currently expected on Dec 18, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Grey Matters Health Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Grey Matters Health Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. Its pipeline includes repirinast for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine for the treatment of strokes and traumatic brain injuries. The company was formerly known as Algernon Health Inc. and changed its name to Grey Matters Health Inc. in April 2026. Algernon Health Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Latest available per-share figures in CAD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
KEEP COMPARING
CA$28.75+CA$0.19 (+0.67%)
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.3% below the high.
CA$33.67+CA$0.85 (+2.59%)
Apotex Health Corp.’s quoted price sits in the upper half of its reported 52-week range, 16.2% below the high.
$13.08-$0.56 (-4.11%)
AbCellera Biologics Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.92% below the high.
$37.54+$1.20 (+3.3%)
Xenon Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.33% below the high.
CA$12.41+CA$2.74 (+28.34%)
Bausch Health Companies Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.9% below the high.
$17.21-$0.15 (-0.86%)
Aurinia Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.6% below the high.
CA$26.76+CA$0.46 (+1.75%)
Extendicare Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.63% below the high.
CA$19.92+CA$0.06 (+0.3%)
Sienna Senior Living Inc.’s quoted price sits in the lower half of its reported 52-week range, 17.24% below the high.
